Nature Reviews Drug Discovery surveys expanding GLP-1 agonist benefits
The journal piece by Kingwell and colleagues reviews evidence for incretin effects reaching beyond glycaemic control and weight loss.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 4 20:00 ETSource: Nature reviews. Drug discovery
The wire
- 01Nature Reviews Drug Discovery published a review on 5 October examining the widening range of reported benefits of GLP-1 receptor agonists.
- 02Clinicians fielding questions about indications beyond diabetes and obesity get a consolidated reference from a major pharmacology journal.
- 03It is a review rather than new data, and only the citation details are available here, so the specific indications and strength of evidence discussed are not detailed.
From the source
Read at pubmed.ncbi.nlm.nih.govProbing the many benefits of GLP-1 receptor agonists
Nature reviews. Drug discovery · 2026 Oct 5 · Kingwell K et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42834104/
